How would you treat HR positive, HER2 positive metastatic breast cancer in patients with a borderline or poor performance status?
Answer from: Medical Oncologist at Academic Institution
For HR positive, HER2 positive metastatic breast cancer in this patient, I would favor a combination with endocrine therapy + trastuzumab, not chemotherapy plus trastuzumab. This combination has been shown to be more effective versus endocrine therapy alone (Huober et al., PMID 21862331) and is incl...
Sign in or Register to read more